Arca
Skip to content
Tools
Tools

Soft tissue sarcoma

Drug research and approvals for soft tissue sarcoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 545 studies of soft tissue sarcoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 14 drug trials for it since 2013, FDA has 8 approved and 55 open orphan designations naming it, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 545
  • Trials authorized in Canada: 14
  • FDA orphan approvals: 8
  • EU medicines: 1

Recruiting now

Newest posted first, of 545 recruiting on ClinicalTrials.gov ↗

Trials authorized in Canada

The 10 newest of 14; search them all in Canada trials
Apr 4, 2025A phase 1b trial of BOLD-100 plus doxorubicin in advanced soft tissue sarcomasBOLD-100University Health NetworkClosed
Jul 18, 2024A multicenter, randomized, phase 3 study to assess the efficacy and safety of intratumorally administered INT230-6 (shao, vinblastine, cisplatin) compared with…INT230-6 (cisplatin-vinblastine)Intensity TherapeuticsOngoing
Feb 12, 2024Randomized phase 2 study of cabozantinib, ipilimumab, and nivolumab in patients with soft tissue sarcomaCabozantinib/ Ipilimumab/ NivolumabPrincess Margaret Cancer CentreClosed
Oct 19, 2020A phase 1 study of metronomic selinexor in select soft tissue sarcomas and split dosing of selinexor in all soft tissue sarcomasSelinexor (KPT-330)Princess Margaret Cancer CentreClosed
Jul 3, 2019A phase 2 study of talimogene laherparepvec (t-vec) and radiation in localized soft tissue sarcomaImlygic (talimogene laherparepvec [t-vec])Princess Margaret Phase I ConsortiumPending
Jun 19, 2019An open-label, multi-center patient access program of olaratumab for the treatment of soft tissue sarcomaOlaratumab (LY3012207)Eli LillyOngoing
Apr 8, 2019A phase 1/2 study to investigate the safety, pharmacokinetics and efficacy of EDO-S101, a first-in-class alkylating histone deacetylase inhibition (HDACI)…Tinostamustine (EDO-S101)Mundipharma Research LimitedClosed
Jul 17, 2018"a phase II randomized controlled trial of neoadjuvant pembrolizumab with radiotherapy and adjuvant pembrolizumab in patients with high-risk, localized soft…KeytrudaMcGill University Health CentrePending
Feb 16, 2018A prospective study of hypoxia imaging in patients with soft tissue sarcoma using positron emission tomography (PET) with 18f-fluoroazomycin arabinoside…18F-fluoroazomycin arabinoside (18F-FAZA)Princess Margaret HospitalOngoing
Sep 9, 2015A randomized, double-blind, placebo-controlled, phase 3 trial of doxorubicin plus olaratumab versus doxorubicin plus placebo in patients with advanced or…LY3012207 (olaratumab) / Doxorubicin hydrochlorideEli LillyOngoing

FDA orphan designations

Approved first, then open designations, newest first; 15 of 63
Jun 17, 2026TecelraTreatment of adults and pediatric patients 12 years of age and older with unresectable or metastatic synovial sarcoma who have received…Uswm CT, LLCApproved
Aug 1, 2024TecelraTreatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P,…Uswm CT, LLCApproved
Dec 9, 2022TecentriqAs a single agent for the treatment of adult and pediatric patients 2 years of age and older with unresectable or metastatic alveolar soft…Genentech, Inc.Approved
Jan 23, 2020TazemetostatTAZVERIK is indicated for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced…Epizyme, Inc.Approved
Oct 19, 2016LartruvoIn combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an…Eli Lilly and CompanyApproved
Jan 28, 2016HalavenTreatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracyclne-containing regimenEisai Inc.Approved
Oct 23, 2015YondelisFor the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing…Janssen Research & Development, LLCApproved
Apr 26, 2012VotrientAdvanced soft tissue sarcoma (STS) who have received prior chemotherapyNovartis Pharmaceuticals CorpApproved
Oct 22, 2026177Lu-FAP-VG11 radionuclide drug conjugateTreatment of soft tissue sarcomaVitsGen Therapeutics Inc.Designated
Sep 22, 2026Synthetic mRNA designed to destabilize 3′UTR (untranslated…Treatment of soft tissue sarcoma, including rhabdomyosarcomaUTR Therapeutics Inc.Designated
Jun 9, 2026Alpha-emitting radiolabeled small molecule that selectively…Treatment of soft tissue sarcomaRatio Therapeutics, Inc.Designated
May 28, 2026Recombinant, single-chain, human Interleukin-12 linked to a…Treatment of soft tissue sarcomaGuidant BioTherapeutics Inc.Designated
May 18, 2026LegubicinTreatment of soft tissue sarcomaCatalysis Therapeutics Inc.Designated
Apr 12, 2026Eftilagimod alfaTreatment of soft tissue sarcomaImmutep S.A.SDesignated
Mar 17, 2026Zika virus strain ZIKV-Nicaragua/2016Treatment of soft tissue sarcoma, including rhabdomyosarcomaThe Nemours FoundationDesignated

Medicines authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
Apr 25, 2025Trabectedin AccordTrabectedin · genericAccord Healthcare S.L.U.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.